These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36502960)

  • 21. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
    Beaudry F; Huot P
    J Neural Transm (Vienna); 2020 Oct; 127(10):1343-1358. PubMed ID: 32860561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Eur J Neurosci; 2024 Mar; 59(6):1169-1176. PubMed ID: 37515363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The highly selective 5-HT
    Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
    Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HT
    Kwan C; Frouni I; Bédard D; Nuara SG; Gourdon JC; Hamadjida A; Huot P
    Exp Brain Res; 2019 Feb; 237(2):435-442. PubMed ID: 30443669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of mGluR
    Frouni I; Kwan C; Bédard D; Hamadjida A; Kang W; Belliveau S; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Nov; 397(11):9135-9147. PubMed ID: 38900249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-parkinsonian activity of the adenosine A
    Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
    Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    Frouni I; Kang W; Bédard D; Belliveau S; Kwan C; Hadj-Youssef S; Bourgeois-Cayer É; Ohlund L; Sleno L; Hamadjida A; Huot P
    Eur J Pharmacol; 2022 Aug; 929():175090. PubMed ID: 35780824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
    Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective blockade of the 5-HT
    Kwan C; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2021 Jan; 182():108386. PubMed ID: 33152452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The adenosine A
    Ohno Y; Okita E; Kawai-Uchida M; Shoukei Y; Soshiroda K; Kanda T; Uchida S
    J Pharmacol Sci; 2023 Jul; 152(3):193-199. PubMed ID: 37257947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
    Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.